Advanced search
Publication Cover
Toxicology Mechanisms and Methods Volume 25, 2015 - Issue 3
Submit an article Journal homepage
374
Views
24
CrossRef citations to date
0
Altmetric
Research Articles

Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid

Jacqueline M. TarrantDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA, Correspondence[email protected]
,
Preeti DhawanDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Jatinder SinghDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA, ;Retrophin Inc., Cambridge, MA, USA,
,
Tanja S. ZabkaDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Emer ClarkeReachBio, Seattle, WA, USA,
,
Garry DosSantosReachBio, Seattle, WA, USA,
,
Peter S. DragovichDepartment of Discovery Chemistry and
,
Deepak SampathDepartment of Translational Oncology, Genentech Inc., South San Francisco, CA, USA, and
,
Tori LinDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Bobbi McCrayDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Nghi LaDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Trung NguyenDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Ariel KaussDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Donna DambachDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Dinah L. MisnerDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
,
Dolores DiazDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA,
&
Hirdesh UppalDepartment of Safety Assessment, Genentech Inc., South San Francisco, CA, USA, ;Medivation, San Francisco, CA, USA
 show all
Pages 201-211 | Received 13 Dec 2014, Accepted 27 Jan 2015, Published online: 20 Apr 2015

References

  • Beauparlant P, Bedard D, Bernier C, et al. (2009). Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 20:346–54
  • Bi TQ, Che XM. (2010). Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 10:119–25
  • Evstatiev R, Bukaty A, Jimenez K, et al. (2014). Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin. Am J Hematol 89:524–9
  • Galli U, Ercolano E, Carraro L, et al. (2008). Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. Chem Med Chem 3:771–9
  • Holen K, Saltz LB, Hollywood E, et al. (2008). The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26:45–51
  • Houtkooper RH, Canto C, Wanders RJ, Auwerx J. (2010). The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31:194–223
  • Hovstadius P, Larsson R, Jonsson E, et al. (2002). A phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 8:2843–50
  • Kenney B, Stack G. (2009). Drug-induced thrombocytopenia. Arch Pathol Lab Med 133:309–14
  • Konieczna IM, Panuganti S, DeLuca TA, et al. (2013). Administration of nicotinamide does not increase platelet levels in mice. Blood Cells Mol Dis 50:171–6
  • Lindhagen E, Hjarnaa PJV, Friberg LE, et al. (2004). Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828. Drug Develop Res 61:218–26
  • Montecucco F, Cea M, Bauer I, et al. (2013). Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets 14:637–43
  • Nahimana A, Attinger A, Aubry D, et al. (2009). The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 113:3276–86
  • Oh A, Ho YC, Zak M, et al. (2014). Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase. ChemBioChem 15:1121–30
  • Olesen UH, Thougaard AV, Jensen PB, Sehested M. (2010). A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther 9:1609–17
  • Pessina A, Albella B, Bayo M, et al. (2003). Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 75:355–67
  • Pessina A, Parent-Massin D, Albella B, et al. (2009). Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. Toxicol In Vitro 23:194–200
  • Pittelli M, Formentini L, Faraco G, et al. (2010). Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem 285:34106–14
  • Schou C, Ottosen ER, Petersen HJ, et al. (1997). Novel cyanoguanidines with potent oral antitumor activity. Bioorg Med Chem Lett 3:3095–100
  • Vander Heiden MG, Cantley LC, Thompson CB. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–33
  • von Heideman A, Berglund A, Larsson R, Nygren P. (2010). Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol 65:1165–72
  • Xiao Y, Elkins K, Durieux JK, et al. (2013). Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618. Neoplasia 15:1151–60
  • Zabka TS, Singh JT, Dhawan P, et al. (2015). Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. Toxicol Sci 144:163–72
  • Zheng X, Bair KW, Bauer P, et al. (2013a). Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Bioorg Med Chem Lett 23:5488–97
  • Zheng X, Bauer P, Baumeister T, et al. (2013b). Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J Med Chem 56:6413–33

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.